The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis

Immunotherapy. 2018 Nov;10(15):1289-1291. doi: 10.2217/imt-2018-0108.

Authors

Elie El Rassy¹, Fadi Farhat¹, Joseph Kattan¹

Affiliation

¹ Department of Medical Oncology, Hotel Dieu de France University Hospital, Faculty of Medicine, Saint Joseph University, Lebanon.

PMID: 30474477
DOI: 10.2217/imt-2018-0108

No abstract available

Keywords: adjuvant; brain metastases; immune checkpoint inhibitors; intracranial; ipilimumab; melanoma; nivolumab; pembrolizumab.

Publication types

Editorial

MeSH terms

B7-H1 Antigen / antagonists & inhibitors
Brain Neoplasms / drug therapy*
Brain Neoplasms / secondary
Clinical Trials as Topic
Humans
Immunotherapy / methods*
Ipilimumab / therapeutic use*
Melanoma / drug therapy*
Melanoma / secondary
Neoplasm Metastasis
Nivolumab / therapeutic use*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Treatment Outcome

Substances

B7-H1 Antigen
Ipilimumab
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab